Moxidectin and the avermectins: Consanguinity but not identity

Roger Prichard (1) , Cécile Menez-Berlioz (2, 3) , Anne Lespine (2, 3)

1 McGill University = Université McGill [Montréal, Canada]
2 ToxAlim - ToxAlim
3 UT3 - Université Toulouse III - Paul Sabatier

The avermectins and milbemycins contain a common macrocyclic lactone (ML) ring, but are fermentation products of different organisms. The principal structural difference is that avermectins have sugar groups at C13 of the macrocyclic ring, whereas the milbemycins are protonated at C13. Moxidectin (MOX), belonging to the milbemycin family, has other differences, including a methoxime at C23. The avermectins and MOX have broad-spectrum activity against nematodes and arthropods. They have similar but not identical, spectral ranges of activity and some avermectins and MOX have diverse formulations for great user flexibility. The longer half-life of MOX and its safety profile, allow MOX to be used in long-acting formulations. Some important differences between MOX and avermectins in interaction with various invertebrate ligand-gated ion channels are known and could be the basis of different efficacy and safety profiles. Modelling of IVM interaction with glutamate-gated ion channels suggest different interactions will occur with MOX. Similarly, profound differences between MOX and the avermectins are seen in interactions with ABC transporters in mammals and nematodes. These differences are important for pharmacokinetics, toxicity in animals with defective transporter expression, and probable mechanisms of resistance. Resistance to the avermectins has become widespread in parasites of some hosts and MOX resistance also exists and is increasing. There is some degree of cross-resistance between the avermectins and MOX, but avermectin resistance and MOX resistance are not identical. In many cases when resistance to avermectins is noticed, MOX produces a higher efficacy and quite often is fully effective at recommended dose rates. These similarities and differences should be appreciated for optimal decisions about parasite control, delaying, managing or reversing resistances, and also for appropriate anthelmintic combination. (C) 2012 Australian Society for Parasitology Published by Elsevier Ltd. All rights reserved.

Mots clés: Avermectin; Ivermectin; Moxidectin; Toxicity; ATP binding cassette transporter; Ligand-gated ion channels; RHIPICEPHALUS BOOPHILUS MICROPLUS; MACROCYCLIC LACTONE ANTHELMINTICS; P-GLYCOPROTEIN DEFICIENCY; LACTATING DAIRY-CATTLE; LOA-LOA ENCEPHALOPATHY; IN-VITRO METABOLISM

Mots clés: Nematode; GATED CHLORIDE CHANNEL; CAMELS CAMELUS-DROMEDARIUS; NT230(DEL4) MDR1 MUTATION; POUR-ON FORMULATIONS

Domaines: Sciences du Vivant [q-bio]

Roger Prichard, Cécile Menez-Berlioz, Anne Lespine. Moxidectin and the avermectins: Consanguinity but not identity. International journal for parasitology. Drugs and drug resistance, 2012, 2, pp.134 - 153. ⟨10.1016/j.ijpddr.2012.04.001⟩. ⟨hal-02649069⟩